Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Hisato Kawakami"'
Autor:
Kaoru Tanaka, Ryoji Kato, Hitomi Sakai, Masayuki Takeda, Kimio Yonesaka, Hisato Kawakami, Kazuhiko Nakagawa, Koji Haratani, Hidetoshi Hayashi, Kazuto Nishio, Kazuko Sakai
Publikováno v:
British Journal of Cancer
Background Cancer-associated fibroblasts (CAFs) in the tumour microenvironment (TME) suppress antitumour immunity, and the tyrosine kinase inhibitor nintedanib has antifibrotic effects. Methods We performed a preclinical study to evaluate whether nin
Autor:
Keiji Furuuchi, Toshimitsu Uenaka, Ryoji Kato, Hitomi Sakai, Yuta Onodera, Elizabeth B. Somers, Hisato Kawakami, Takeshi Teramura, Kazuhiko Nakagawa
Publikováno v:
Clinical and Translational Medicine
Clinical and Translational Medicine, Vol 11, Iss 6, Pp n/a-n/a (2021)
Clinical and Translational Medicine, Vol 11, Iss 6, Pp n/a-n/a (2021)
Background The main function of folate receptor α (FOLRα) has been considered to mediate intracellular folate uptake and induce tumor cell proliferation. Given the broad spectrum of expression among malignant tumors, including gastric cancer (GC) b
Autor:
Hisato Kawakami, Shengbing Huang, Kaixiong Tao, Klaus Strebhardt, Frank A. Sinicrope, Xiangyu Zeng, Weizhen Liu, Peng Zhang
Publikováno v:
Molecular Cancer Research. 16:378-389
The BRAFV600E mutation occurs in approximately 8% of human colorectal cancers and is associated with therapeutic resistance that is due, in part, to reactivation of MEK/ERK signaling cascade. Recently, pathway analysis identified cyclin-dependent kin
Autor:
Naoki Takegawa, Junji Tsurutani, Masayuki Takeda, Hidetoshi Hayashi, Takeshi Yoshida, Kimio Yonesaka, Junko Tanizaki, Hisato Kawakami, Satomi Watanabe, Kazuhiko Nakagawa
Publikováno v:
Molecular Cancer Therapeutics. 16:2563-2571
T790M mutation–selective EGFR tyrosine kinase inhibitors (EGFR-TKI) have demonstrated clinical benefits in non–small cell lung cancer (NSCLC) patients harboring T790M mutation, which is the major cause of resistance to EGFR-TKI. However, their ef
Autor:
Shamit K. Dutta, Debabrata Mukhopadhyay, Hisato Kawakami, Shengbing Huang, Krishnendu Pal, Frank A. Sinicrope
Publikováno v:
Molecular Cancer Therapeutics. 15:3015-3027
Oncogenic BRAFV600E mutations activate MAPK signaling and are associated with treatment resistance and poor prognosis in patients with colorectal cancer. In BRAFV600E-mutant colorectal cancers, treatment failure may be related to BRAFV600E-mediated a
Autor:
Khashayarsha Khazaie, Aziz Zaanan, Hisato Kawakami, Frank A. Sinicrope, Shengbing Huang, Koichi Okamoto
Publikováno v:
Journal of Biological Chemistry. 290:23838-23849
In colorectal cancers with oncogenic GTPase Kras (KRAS) mutations, inhibition of downstream MEK/ERK signaling has shown limited efficacy, in part because of failure to induce a robust apoptotic response. We studied the mechanism of apoptosis resistan
Publikováno v:
Molecular Cancer Research. 13:659-669
KRAS mutations are frequently detected in human colorectal cancer and contribute to de novo apoptosis resistance and ultimately therapeutic failure. To overcome KRAS-mediated apoptosis resistance, the irreversible proteasome inhibitor, carfilzomib, w
Autor:
Kenji Hirotani, Kazuko Sakai, Satomi Watanabe, Hisato Kawakami, Takashi Kagari, Naoyuki Maeda, Kazuhiko Nakagawa, Koji Haratani, Naoki Takegawa, Kimio Yonesaka, Yasutaka Chiba, Kazuto Nishio
Publikováno v:
Oncogene. 38(9)
EGFR tyrosine kinase inhibitors (TKIs) are standard therapy for EGFR-mutant non-small cell lung cancer (NSCLC); however, these tumours eventually acquire chemoresistance. U3-1402 is an anti-HER3 antibody-drug conjugate with a novel topoisomerase I in
Autor:
Masayuki Takeda, Junko Tanizaki, Hidetoshi Hayashi, Naoki Takegawa, Koji Haratani, Yoshikane Nonagase, Takeshi Yoshida, Satomi Watanabe, Takayuki Takahama, Kimio Yonesaka, Hiroto Ueda, Takao Tamura, Junji Tsurutani, Hisato Kawakami, Kazuhiko Nakagawa, Yasutaka Chiba
Publikováno v:
Oncotarget
// Yoshikane Nonagase 1 , Kimio Yonesaka 1 , Hisato Kawakami 1 , Satomi Watanabe 1 , Koji Haratani 1 , Takayuki Takahama 1 , Naoki Takegawa 1 , Hiroto Ueda 1 , Junko Tanizaki 1 , Hidetoshi Hayashi 1 , Takeshi Yoshida 1 , Masayuki Takeda 1 , Yasutaka
Autor:
Hisato Kawakami, Kazuto Nishio, Kazuhiko Nakagawa, Kazuyoshi Yanagihara, Shinya Ueda, Shinichi Nishina, Wataru Okamoto, Isamu Okamoto, Takayasu Kurata, Tokuzo Arao
Publikováno v:
Molecular Cancer Therapeutics. 11:1557-1564
Therapeutic strategies that target the tyrosine kinase MET hold promise for gastric cancer, but the mechanism underlying the antitumor activity of such strategies remains unclear. We examined the antitumor action of the MET tyrosine kinase inhibitor